Onco Wiki / Indication

Breast cancer (invasive) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Tracksurveillance
Linked regimenNone
IDIND-LI-FRAUMENI-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE
TypeIndication
Statusreviewed 2026-05-18 | pending_clinical_signoff
DiseasesDIS-BREAST
SourcesSRC-NCCN-BREAST-2025 SRC-NCCN-CNS-2025 SRC-NCCN-SARCOMA

Notes

STUB — alternative-track companion for Li-Fraumeni Syndrome hereditary prevention pilot. §15.2 C4 ≥2-tracks invariant compliance. Resource-intensive empirical pathway framed explicitly as patient-autonomy alternative per CHARTER §11 — production version may add a quantitative cost-effectiveness annotation.

Used By

Algorithms

Red flag